Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Keros Therapeutics Inc (KROS)

Keros Therapeutics Inc (KROS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Keros Therapeutics Inc 1050 WALTHAM STREET SUITE 302 LEXINGTON MA 02421 USA

www.kerostx.com P: 617-314-6297

Description:

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel treatments for hematological and musculoskeletal disorders. The company's product pipeline consists of KER-050, KER-047and KER-012 which are in clinical stage. Keros Therapeutics, Inc. is based in LEXINGTON, MA.

Key Statistics

Overview:

Market Capitalization, $K 2,173,458
Enterprise Value, $K 1,842,308
Shares Outstanding, K 36,068
Annual Sales, $ 150 K
Annual Net Income, $ -152,990 K
Last Quarter Sales, $ 140 K
Last Quarter Net Income, $ -40,240 K
EBIT, $ -169,950 K
EBITDA, $ -169,130 K
60-Month Beta 1.32
% of Insider Shareholders 22.90%
% of Institutional Shareholders 71.56%
Float, K 27,808
% Float 77.10%
Short Volume Ratio 0.32

Growth:

1-Year Return 36.58%
3-Year Return 23.31%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.34 on 02/28/24
Latest Earnings Date 05/02/24
Earnings Per Share ttm -5.20
EPS Growth vs. Prev Qtr -0.75%
EPS Growth vs. Prev Year -22.94%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

KROS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -46.74%
Return-on-Assets % -42.59%
Profit Margin % -101,993.33%
Debt/Equity 0.00
Price/Sales 14,467.81
Price/Cash Flow N/A
Price/Book 5.15
Book Value/Share 11.09
Interest Coverage -3.39
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar